Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years?
Authors
Evans, D. G.Howell, Sacha J
Burghel, G. J.
Forde, C.
Lalloo, F.
Smith, M. J.
Howell, A.
Gandhi, A.
Woodward, E. R.
Affiliation
The Christie NHS Foundation Trust, Manchester, UKIssue Date
2024
Metadata
Show full item recordCitation
Evans DG, Howell SJ, Burghel GJ, Forde C, Lalloo F, Smith MJ, et al. Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years? Journal of medical genetics. 2024 2024 JUL 25. PubMed PMID: WOS:001279890700001. English.Journal
Journal of Medical GeneticsPubMed ID
39054051Language
enCollections
Related articles
- Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany.
- Authors: Hamann U, Liu X, Lange S, Ulmer HU, Benner A, Scott RJ
- Issue date: 2002 Mar
- Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
- Authors: Van Marcke C, Helaers R, De Leener A, Merhi A, Schoonjans CA, Ambroise J, Galant C, Delrée P, Rothé F, Bar I, Khoury E, Brouillard P, Canon JL, Vuylsteke P, Machiels JP, Berlière M, Limaye N, Vikkula M, Duhoux FP
- Issue date: 2020 Apr 15
- Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years.
- Authors: Garrett A, Talukdar S, Izatt L, Brady AF, Whyte S, Josephs KS, Shanmugasundaram M, Guillemot LS, Vakili D, Ey S, Ahmed M
- Issue date: 2022 Jun
- Germline BRCA1 and BRCA2 testing for breast cancer survivors.
- Authors: Wiggins J, McLoughlin A, George A, Ring A, Kemp Z
- Issue date: 2020 Aug